Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients. Prograf is currently used as part of the standard immunosuppression regimen for LT recipients at UHN. This study will compare the use of Prograf and Envarsus and their effects on liver and renal function, trough tacrolimus levels, drug-related adverse effects, and patient adherence. Trial design is a pilot randomized trial. The study aims to recruit 40 patients from UHN's LT program and they will be randomized 1:1 to either stay on their current dose of Prograf or be converted to a once-daily equivalent dose of Envarsus. Both groups of patients will be followed for 48 weeks. This study will compare the change from baseline to week 48 in liver and renal function, tacrolimus-related side effects and patient reported outcomes between the two study groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in AST levels
Timeframe: Baseline to week 12
Change in ALT levels
Timeframe: Baseline to week 12
Change in ALP levels
Timeframe: Baseline to week 12
Change in Bilirubin blood levels
Timeframe: Baseline to week 12
Change in tacrolimus trough levels
Timeframe: Baseline to week 12
Change in overall daily dose of tacrolimus
Timeframe: Baseline to week 12